Fexinidazole Winthrop H-W-2320

Name of the medicinal product Fexinidazole Winthrop
Opinion holder

sanofi-aventis groupe

54 rue La Boétie
75008  Paris
France
Active substance Fexinidazole
International non-proprietary name or common name Fexinidazole
Pharmaco-therapeutic group

Antiparasitic products, antiprotozoals, agents against leishmaniasis and trypanosomiasis, nitroimidazole derivatives

ATC code Not yet assigned
Therapeutic indication

Fexinidazole Winthrop is indicated for the treatment of both first-stage (haemo-lymphatic) and second-stage (meningo-encephalitic) of human African trypanosomiasis (HAT) due to Trypanosoma brucei gambiense in adults and children ≥ 6 years old and weighing ≥ 20 kg. Fexinidazole should be used in line with official recommendations.

Orphan medicinal product designation date Not applicable

*This document includes:

Annex I - Summary of product characteristics
Annex IIA - Manufacturer responsible for batch release
Annex IIB - Recommendations to the opinion holder - conditions of use
Annex IIIA - Labelling
Annex IIIB - Package leaflet

Please note that the size of the above document can exceed 50 pages.
You are therefore advised to be selective about which sections or pages you wish to print.

How useful was this page?

Add your rating
Average
1 rating